Chronic Myeloid Leukemia Treatments
Chronic Myeloid Leukemia Treatments is a research topic within Hematology. Science Explorer counts 31k research works in it since 1950. 14.5% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the efficacy and resistance of various tyrosine kinase inhibitors, such as Imatinib, Dasatinib, and Nilotinib, in the treatment of Chronic Myeloid Leukemia (CML). The papers discuss molecular mechanisms of resistance, mutation analysis, leukemia stem cells, treatment discontinuation, and long-term outcomes of different targeted therapies.
- Imatinib
- BCR-ABL
- Tyrosine Kinase Inhibitors
- Resistance
- Mutation
- Leukemia Stem Cells
- Molecular Response
- Treatment Discontinuation
- Dasatinib
- Nilotinib
- Research works
- 31k fractional, since 1950
- In the world top 10%
- 4.5k per year above
- Top-10% rate
- 14.5% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +13% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Chronic Myeloid Leukemia Treatments research?
By volume, the United States and China publish the most (1.7k and 770 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.7k works
- 2 China 770 works
- 3 India 284 works
- 4 Italy 275 works
- 5 Japan 265 works
- 6 Germany 227 works
- 7 Brazil 207 works
- 8 France 187 works
- 9 United Kingdom 167 works
- 10 Spain 136 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Chronic Myeloid Leukemia Treatments research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Chronic Myeloid Leukemia Treatments research, followed by Chinese Academy of Medical Sciences & Peking Union Medical College and Moffitt Cancer Center.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer CenterUnited States 159 works
- 2 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 31 works
- 3 Moffitt Cancer CenterUnited States 26 works
- 4 Memorial Sloan Kettering Cancer CenterUnited States 26 works
- 5 Peking UniversityChina 25 works
- 6 Cleveland ClinicUnited States 25 works
- 7 Dana-Farber Cancer InstituteUnited States 25 works
- 8 Institute of Hematology & Blood Diseases HospitalChina 25 works
- 9 Icahn School of Medicine at Mount SinaiUnited States 19 works
- 10 Peking University People's HospitalChina 19 works
Who are the leading researchers in Chronic Myeloid Leukemia Treatments?
The most-cited researchers publishing on Chronic Myeloid Leukemia Treatments include Todd R. Golub and Hagop M. Kantarjian.
- 1 Todd R. Golub United States 6.8k citations
- 2 Hagop M. Kantarjian United States 4k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Chronic Myeloid Leukemia Treatments research done?
The largest centres of Chronic Myeloid Leukemia Treatments research in 2022–2025 are Houston (United States), Beijing (China), New York (United States) and Boston (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Houston and Tampa.
Largest cities, 2022–2025
Where it is the local speciality
- HoustonUS · 182.1 works13×
- TampaUS · 35.3 works9.3×
Location quotient: how much more of its research is in Chronic Myeloid Leukemia Treatments than the world average.
Where is the best place to study Chronic Myeloid Leukemia Treatments?
Among universities, judged by research, Medical College of Wisconsin, Post Graduate Institute of Medical Education and Research and Oregon Health & Science University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Medical College of WisconsinUnited States | 57.1 | 10.9% | 12.6× | 17 | +172.5% |
| 2 | Post Graduate Institute of Medical Education and ResearchIndia | 51.8 | 24.5% | 6.0× | 11 | +54.5% |
| 3 | Oregon Health & Science UniversityUnited States | 49.4 | 13.7% | 10.2× | 17 | -22.8% |
| 4 | King Saud UniversitySaudi Arabia | 46.9 | 17.2% | 2.5× | 12 | +151.5% |
| 5 | University of Alabama at BirminghamUnited States | 44.1 | 11.7% | 5.0× | 13 | +249.9% |
| 6 | University of PennsylvaniaUnited States | 43.2 | 23.9% | 2.2× | 11 | +59.7% |
| 7 | First Pavlov State Medical University of St. PetersburgRussia | 41.1 | 0.4% | 22.4× | 8 | +742.6% |
| 8 | Washington University in St. LouisUnited States | 39.2 | 15.2% | 3.8× | 14 | +77.2% |
| 9 | University of ChicagoUnited States | 38.8 | 18.5% | 3.6× | 16 | +0.9% |
| 10 | Icahn School of Medicine at Mount SinaiUnited States | 38.3 | 7.5% | 7.3× | 19 | +16.8% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Chronic Myeloid Leukemia Treatments research growing?
Output in 2018–2022 was 13% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Chronic Myeloid Leukemia Treatments.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.